First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males

Human Reproduction

Volumn 16, Issue 8, 2001, Pages 1592-1597

  Bouloux, P M G ^a   Handelsman, D J ^b   Jockenhovel F ^c   Nieschlag, E ^d   Rabinovici, J ^e   Frasa, W L H ^f   De Bie, J J ^f   Voortman, G ^f   Itskovitz Eldor, J ^g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

^f NV ORGANON   (Netherlands)

^g RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CELL PROTEIN; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; FOLLITROPIN C TERMINAL PEPTIDE; INHIBIN B; LUTEINIZING HORMONE; ORG 36286; RECOMBINANT FOLLITROPIN; RECOMBINANT HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHO CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE INFERTILITY; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INJECTION; INJECTION SITE; INJURY; MALE; MALE INFERTILITY; MULTICENTER STUDY; PERIODONTAL DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PROTEIN DETERMINATION; SKIN DISEASE;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0034883220     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.8.1592     Document Type: Article

References (13)

1. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction
2. Glycoprotein hormone structure-function and analog design
3. Disappearance of exogenously administered human chorionic gonadotropin
4. Asparagine-linked oligosaccharides facilitate human chorionic gonadotropin beta-subunit folding but not assembly of prefolded beta with alpha
5. Inhibin B plasma concentrations in oligozoospermic subjects before and after therapy with follicle stimulating hormone
6. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism
7. Functional homodimeric glycoprotein hormones: Implications for hormone action and evolution
8. What are the clinical benefits of recombinant gonadotrophins?: The development of recombinant FSH Puregon®: A scientific business
9. Biological and immunological characterization of inhibin forms in human plasma
10. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin
11. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism
12. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone Puregon® by Pen-injector and syringe
13. Bioassays of follicle stimulating hormone